Impact of Precision-Guided Dosing on Clinical Decision-Making and Health Care Utilization in Inflammatory Bowel Disease: A Retrospective Pretest/Posttest Real-World Study.

ABSTRACT:

Background

Precision-guided dosing (PGD) is a personalized tool that optimizes clinical decision-making in the treatment of inflammatory bowel disease (IBD) with infliximab (IFX) and its biosimilars. PGD employs nonlinear mixed-effect models using patient-specific pharmacokinetic parameters to predict infliximab trough concentrations without the need to wait until the actual trough measurement. This approach calculates patient-specific clearance (CL) and provides tailored IFX dosing and administration intervals aimed at achieving target trough levels. Implementing PGD can enhance treatment outcomes in IBD patients and may potentially reduce healthcare expenditures.

Methods

We conducted a multicenter, retrospective study as a follow up to our previous clinical experience prog

SUBMITTER: Arai R 

PROVIDER: S-EPMC12305531 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature